<DOC>
	<DOCNO>NCT01262963</DOCNO>
	<brief_summary>The study Phase 1 , open-label study design characterize absorption , distribution , metabolism excretion GSK2118436 follow administration single oral 14C label dose GSK2118436 suspension subject BRAF mutation positive tumor .</brief_summary>
	<brief_title>An Absorption , Distribution , Metabolism Excretion ( ADME ) Study Single Oral Dose 14C GSK2118436 Subjects With BRAF Mutant Solid Tumors</brief_title>
	<detailed_description>GSK2118436 orally administer , potent selective small molecule BRAF inhibitor develop treatment BRAF mutation-positive tumor . The study Phase 1 , open-label study design characterize absorption , distribution , metabolism excretion GSK2118436 follow administration single oral 14C label dose GSK2118436 suspension subject BRAF mutation positive tumor . A sufficient number subject enrol complete approximately four subject . Following completion study , subject may continue dose GSK2118436 rollover study , BRF114144 .</detailed_description>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Male female least 18 year age time sign informed consent form ; Capable give write informed consent , include compliance requirement restriction list consent form ; Body weight &gt; = 45 kg body mass index ( BMI ) &gt; /= 19 kg/m2 &lt; /= 35 kg/m2 ( inclusive ) ; Able swallow retain oral medication ; BRAF mutationpositive tumor ( V600 E/K mutation ) determine via relevant genetic testing ; Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 [ Oken , 1982 ] ; NOTE : Subjects ECOG performance status 2 may eligible approval GSK Medical Monitor Women childbearing potential men reproductive potential must willing practice acceptable method birth control . Additionally , woman childbearing potential must negative serum pregnancy test within 14 day prior first dose study treatment ; Must adequate organ function define follow value : Absolute neutrophil count ( ANC ) &gt; /=1.2 x 10^9/L Hemoglobin &gt; /=9 g/dL Platelets &gt; /=100 x 10^9/L Serum bilirubin &lt; /=1.5 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; /= 2.5 x ULN ; &lt; 5 x ULN liver metastasis present ( approval GSK medical monitor ) Serum creatinine &lt; /= ULN calculate creatinine clearance &gt; /= 60 mL/min Prothrombin time ( PT ) /International normalize ratio ( INR ) partial thromboplastin time ( PTT ) &lt; /=1.3 x ULN Left ventricular ejection fraction &lt; /= institutional low limit normal ECHO Currently receive cancer therapy ( e.g. , chemotherapy delay toxicity , extensive radiation therapy , immunotherapy , biologic therapy , major surgery ) within last three week ; chemotherapy regimens without delayed toxicity within last two week ; use investigational anticancer drug within four week precede first dose GSK2118436 ; Current use prohibit medication require medication study ; Consumption red wine , Seville oranges , grapefruit grapefruit juice seven day prior first dose study medication ; Current use therapeutic warfarin ( note : low molecular weight heparin prophylactic lowdose warfarin permit ) ; History sensitivity heparin heparininduced thrombocytopenia ; The radiation exposure previous three year period 10 millisieverts ( mSv ) subject expose ionize radiation background result work radiation Category A ( classify ) worker result research study may involve . Subjects exclude exposure level verify . Clinical ( therapeutic diagnostic ) exposure include ; An occupation require monitor radiation exposure , nuclear medicine procedure excessive xrays within past 12 month ; Any major surgery within last four week ; Unresolved toxicity equal great National Cancer Institute Common Terminology Criteria Adverse Events , version 4.0 ( NCI CTCAE v4.0 ) [ NCI , 2009 ] Grade 2 previous anticancer therapy except alopecia ; Presence active gastrointestinal disease condition ( e.g. , gastrectomy , bariatric surgery , small bowel large bowel resection ) may interfere significantly absorption drug . If clarification need whether condition significantly affect absorption drug , contact GSK medical monitor permission enroll subject ; A history know Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) infection ( subject laboratory evidence HBV clearance may enrol permission GSK medical monitor ) ; Patients history malignancy definitively treat enrolled approval GSK medical monitor ; Subjects brain metastasis exclude brain metastasis either : Symptomatic Treated ( surgery , radiation therapy ) clinically radiographically stable one month local therapy , Asymptomatic untreated &gt; 1 cm long dimension Patients small ( &lt; /= 1 cm long dimension ) , asymptomatic brain metastasis need immediate local therapy enrol approval GSK medical monitor . Subjects stable dose corticosteroid one month , corticosteroid least two week enrol approval GSK medical monitor . Subjects must also enzymeinducing anticonvulsant four week ; History alcohol drug abuse within six month prior screen ; Corrected QT ( QTc ) interval &gt; /= 480 msec ; History acute coronary syndrome ( include unstable angina ) , coronary angioplasty , stenting within past 24 week ; Class II , III , IV heart failure define New York Heart Association ( NYHA ) functional classification system ; abnormal cardiac valve morphology document echocardiogram ( subject minimal abnormality [ ie , mild regurgitation/stenosis ] enter study approval GSK medical monitor ) ; history know cardiac arrhythmia ( except sinus arrhythmia ) within past 24 week ; Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study drug , excipients ( note : date know drug chemically related GSK2118436 approve Food Drug Administration ) ; Uncontrolled medical condition ( e.g. , diabetes mellitus , hypertension ) , psychological , familial , sociological , geographical condition permit compliance protocol ; unwillingness inability follow procedure require protocol ; Subjects know glucose 6 phosphate dehydrogenase ( G6PD ) deficiency ; The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , five halflives twice duration biological effect investigational product ( whichever longer ) ; Where participation study would result donation blood blood product excess 500 mL within 56 day period ; Pregnant female determine positive pregnancy test screen prior dosing ; Lactating females actively breast feeding ; Subject mentally legally incapacitate ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>GSK2118436</keyword>
	<keyword>BRAF inhibitor</keyword>
	<keyword>BRAF positive tumor</keyword>
	<keyword>ADME</keyword>
	<keyword>Oncology</keyword>
</DOC>